SINPHAR
杏輝藥品工業股份有限公司
SINPHAR is a Taiwan TWSE-listed biotechnology company; its most advanced asset is SB03 (Marketing authorization obtained; marketed, Genital warts), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| SB03 | — | Marketing authorization obtained; marketed | Genital warts | Taiwan | — | Company disclosure |
| ST01 | — | Phase 2 authorized; preparation for trial execution | Dementia | Taiwan, United States | — | Company disclosure |
| SB01 | — | — | — | — | — | Company disclosure |
Key events
No verified events in the past twelve months.
Related Drugnews articles
No related articles in this language.